Study of photosensitizers pharmacokinetics in mouse tumor model by transillumination fluorescence imaging in vivo

Author(s):  
Marina V. Shirmanova ◽  
Irina V. Balalaeva ◽  
Marina A. Sirotkina ◽  
Natalya Yu. Lekanova ◽  
Ilya V. Turchin ◽  
...  
Oncogenesis ◽  
2020 ◽  
Vol 9 (10) ◽  
Author(s):  
Zhongqin Gong ◽  
Hao Jia ◽  
Jianqing Yu ◽  
Yi Liu ◽  
Jianwei Ren ◽  
...  

Abstract The status of FOXP3 and its isoforms in hepatocellular carcinoma (HCC) is unclear. We aimed to investigate the expression and function of FOXP3 and its isoforms in HCC. The study was performed on 84 HCC patients, HCC cell lines and a mouse tumor model. The levels of FOXP3 and its isoforms were determined by nested PCR, quantitative real-time PCR and immunohistochemistry (IHC) staining. The correlation between their levels and clinicopathologic characteristics was analyzed. The full length of FOXP3 (FOXP3) and exon 3-deleted FOXP3 (FOXP3Δ3) were found to be the major isoforms in HCC. The levels of FOXP3Δ3 mRNA and protein in HCC tumor samples were not significantly different from their adjacent normal tissues. The high expression of FOXP3 protein in HCC patients showed a good overall survival. The overexpression of FOXP3 significantly reduced tumor cell proliferation, migration and invasion. The immunofluorescence result indicated that FOXP3 needed to be translocated into the nucleus to exert its inhibitory function. The luciferase assay demonstrated that FOXP3 could be synergistic with Smad2/3/4 to inhibit the oncogene c-Myc. The co-immunoprecipitation results further revealed that FOXP3 could interact with Smad2/3/4. The chromatin immunoprecipitation (ChIP) assay showed that both FOXP3 and Smad2/3/4 bound the promoter of the c-Myc to inhibit it. The in vivo mouse tumor model study confirmed the inhibitory effect of FOXP3. Collectively, the expression of tumor FOXP3 can inhibit the growth of HCC via suppressing c-Myc directly or indirectly via interacting with Smad2/3/4. Therefore, FOXP3 is a tumor suppressor in HCC.


1998 ◽  
Vol 177 (3) ◽  
pp. 523-528 ◽  
Author(s):  
Gregory S. Pari ◽  
Dale Netski ◽  
Stephen St. Jeor ◽  
Donna McCarthy ◽  
Jean Smith ◽  
...  

2005 ◽  
Vol 102 (9) ◽  
pp. 3419-3422 ◽  
Author(s):  
P. J. Pickhardt ◽  
R. B. Halberg ◽  
A. J. Taylor ◽  
B. Y. Durkee ◽  
J. Fine ◽  
...  

2020 ◽  
Author(s):  
Zhongqin Gong ◽  
Hao Jia ◽  
Jianqing Yu ◽  
Yi Liu ◽  
Jianwei Ren ◽  
...  

Abstract Background The status of FOXP3 and its isoforms in hepatocellular carcinoma (HCC) is unclear. We aimed to investigate the expression and function of FOXP3 and its isoforms in HCC. Methods The study was performed on 84 HCC patients, HCC cell lines and a mouse tumor model. The levels of FOXP3 and its isoforms were determined by nested PCR, quantitative real-time PCR and immunohistochemistry (IHC) staining. The correlation between their levels and clinicopathologic characteristics was analyzed. Results The full length of FOXP3 (FOXP3) and exon 3-deleted FOXP3 (FOXP3Δ3) were found to be the major isoforms in HCC. The levels of FOXP3Δ3 mRNA and protein in HCC tumor samples were not significantly different from their adjacent normal tissues. The high expression of FOXP3 protein in HCC patients showed a good overall survival. The overexpression of FOXP3 significantly reduced tumor cell proliferation, migration and invasion. The immunofluorescence result indicated that FOXP3 needed to be translocated into the nucleus to exert its inhibitory function. The luciferase assay demonstrated that FOXP3 could be synergistic with Smad2/3/4 to inhibit the oncogene c-Myc. The co-immunoprecipitation results further revealed that FOXP3 could interact with Smad2/3/4. The chromatin immunoprecipitation (ChIP) assay showed that both FOXP3 and Smad2/3/4 bound the promoter of the c-Myc to inhibit it. The in vivo mouse tumor model study confirmed the inhibitory effect of FOXP3. Conclusion Collectively, the expression of tumor FOXP3 can inhibit the growth of HCC via suppressing c-Myc directly or indirectly via interacting with Smad2/3/4. Therefore, FOXP3 is a tumor suppressor in HCC.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Nhat Quang Bui ◽  
Soon-Woo Cho ◽  
Madhappan Santha Moorthy ◽  
Sang Min Park ◽  
Zhonglie Piao ◽  
...  

2005 ◽  
Vol 4 (6) ◽  
pp. 603-613 ◽  
Author(s):  
Mohamed K. Khan ◽  
Shraddha S. Nigavekar ◽  
Leah D. Minc ◽  
Muhammed S. T. Kariapper ◽  
Bindu M. Nair ◽  
...  

Our results indicate that the surface chemistry, composition, and 3-D structure of nanoparticles are critical in determining their in vivo biodistribution, and therefore the efficacy of nanodevice imaging and therapies. We demonstrate that gold/dendrimer nanocomposites in vivo, present biodistribution characteristics different from PAMAM dendrimers in a B16 mouse tumor model system. We review important chemical and biologic uses of these nanodevices and discuss the potential of nanocomposite devices to greatly improve cancer imaging and therapy, in particular radiation therapy. We also discuss major issues confronting the use of nanoparticles in the near future, with consideration of toxicity analysis and whether biodegradable devices are needed or even desirable.


2012 ◽  
Vol 50 (05) ◽  
Author(s):  
Z Nagy ◽  
B Barták ◽  
S Spisák ◽  
B Wichmann ◽  
A Kalmár ◽  
...  

EBioMedicine ◽  
2021 ◽  
Vol 67 ◽  
pp. 103345
Author(s):  
Ryuhei Okada ◽  
Aki Furusawa ◽  
Daniel W. Vermeer ◽  
Fuyuki Inagaki ◽  
Hiroaki Wakiyama ◽  
...  

Radiology ◽  
2003 ◽  
Vol 228 (2) ◽  
pp. 560-568 ◽  
Author(s):  
Samira Guccione ◽  
Yi-Shan Yang ◽  
Gongyi Shi ◽  
Daniel Y. Lee ◽  
King C. P. Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document